AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sotagliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sodium glucose co-transporter inhibitors, phlorizin derivatives | 5339 | 1018899-04-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sotagliflozin is a dual inhibitor of sodium glucose cotransporter type 1 (SGLT1) and SGLT2. Local intestinal inhibition of SGLT1, the major transporter for glucose absorption, delays and reduces glucose absorption in the proximal intestine, resulting in a blunting and delay of postprandial hyperglycaemia. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, sotagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,BRAF,BTK,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1,ZAP70 | 23 | |||
| kinase-selectivity-class | AXL,GRK2,MAP2K6 | 3 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 5.284 | Moderate | 0.71 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| rat-kpuu-brain | Rat brain Kpuu | 0.116 | % | Moderate | 0.71 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 26, 2019 | EMA | SANOFI-AVENTIS GROUPE | |
| May 26, 2023 | FDA | LEXICON PHARMS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BK06 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
| MeSH PA | D000077203 | Sodium-Glucose Transporter 2 Inhibitors |
| MeSH PA | D007004 | Hypoglycemic Agents |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors |
| FDA EPC | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:73273 | sodium-glucose transport protein subtype 2 inhibitor |
| CHEBI has role | CHEBI:77307 | cardioprotective agent |
| CHEBI has role | CHEBI:229227 | sodium-glucose transport protein subtype 1 inhibitor |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 at increased risk of cardiovascular disease | indication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | indication | 46635009 | DOID:9744 |
| Heart failure | indication | 84114007 | DOID:6000 |
| Chronic kidney disease at increased risk of cardiovascular disease | indication | 709044004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.45 | acidic |
| pKa2 | 13.37 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 200MG | INPEFA | LEXICON PHARMS INC | N216203 | May 26, 2023 | RX | TABLET | ORAL | 7781577 | May 4, 2028 | REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS |
| 400MG | INPEFA | LEXICON PHARMS INC | N216203 | May 26, 2023 | RX | TABLET | ORAL | 7781577 | May 4, 2028 | REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS |
| 200MG | INPEFA | LEXICON PHARMS INC | N216203 | May 26, 2023 | RX | TABLET | ORAL | 8476413 | May 29, 2028 | REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS |
| 400MG | INPEFA | LEXICON PHARMS INC | N216203 | May 26, 2023 | RX | TABLET | ORAL | 8476413 | May 29, 2028 | REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 200MG | INPEFA | LEXICON PHARMS INC | N216203 | May 26, 2023 | RX | TABLET | ORAL | May 26, 2028 | NEW CHEMICAL ENTITY |
| 400MG | INPEFA | LEXICON PHARMS INC | N216203 | May 26, 2023 | RX | TABLET | ORAL | May 26, 2028 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 8.75 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Sodium/glucose cotransporter 1 | Transporter | INHIBITOR | IC50 | 7.44 | SCIENTIFIC LITERATURE | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 6B4ZBS263Y | UNII |
| 4042306 | VANDF |
| C3502471 | UMLSCUI |
| CHEBI:229226 | CHEBI |
| LFL | PDB_CHEM_ID |
| CHEMBL3039507 | ChEMBL_ID |
| 24831714 | PUBCHEM_CID |
| DB12713 | DRUGBANK_ID |
| D10669 | KEGG_DRUG |
| 9824 | INN_ID |
| C575681 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8312 | IUPHAR_LIGAND_ID |
| 367663 | MMSL |
| 41581 | MMSL |
| d10056 | MMSL |
| 019461 | NDDF |
| 2638675 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| INPEFA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70183-220 | TABLET | 200 mg | ORAL | NDA | 30 sections |
| INPEFA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70183-221 | TABLET | 200 mg | ORAL | NDA | 30 sections |
| INPEFA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70183-240 | TABLET | 400 mg | ORAL | NDA | 30 sections |
| INPEFA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70183-241 | TABLET | 400 mg | ORAL | NDA | 30 sections |